The stock of Intellia Therapeutics Inc (NASDAQ:NTLA) is a huge mover today! About 176,858 shares traded hands. Intellia Therapeutics Inc (NASDAQ:NTLA) has risen 6.00% since October 1, 2016 and is uptrending. It has outperformed by 2.53% the S&P500.
The move comes after 5 months positive chart setup for the $497.96 million company. It was reported on Oct, 31 by Barchart.com. We have $37.18 PT which if reached, will make NASDAQ:NTLA worth $846.53 million more.
Analysts await Intellia Therapeutics Inc (NASDAQ:NTLA) to report earnings on November, 3. After $-0.36 actual earnings per share reported by Intellia Therapeutics Inc for the previous quarter, Wall Street now forecasts -41.67% EPS growth.
Intellia Therapeutics Inc (NASDAQ:NTLA) Ratings Coverage
Out of 4 analysts covering Intellia Therapeutics (NASDAQ:NTLA), 4 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Intellia Therapeutics has been the topic of 5 analyst reports since May 31, 2016 according to StockzIntelligence Inc. The stock has “Buy” rating given by Jefferies on Friday, August 5. The stock has “Outperform” rating given by Wedbush on Tuesday, May 31. The rating was initiated by Jefferies on Tuesday, May 31 with “Hold”. Credit Suisse initiated it with “Outperform” rating and $39 target price in Tuesday, May 31 report. Leerink Swann upgraded Intellia Therapeutics Inc (NASDAQ:NTLA) on Friday, August 5 to “Outperform” rating.
According to Zacks Investment Research, “Intellia Therapeutics, Inc. is a genome editing company focused on the development of curative therapeutics using a biological tool, CRISPR/Cas9 system. Intellia Therapeutics, Inc. is headquartered in Cambridge, Massachusetts.”
More important recent Intellia Therapeutics Inc (NASDAQ:NTLA) news were published by: Marketwatch.com which released: “/quotes/zigman/3870025/realtime” on April 16, 2016, also Bostonglobe.com published article titled: “Space is at a premium for Cambridge startup Intellia”, Globenewswire.com published: “Intellia Therapeutics to Present at 2016 Wedbush PacGrow Healthcare Conference” on August 10, 2016. More interesting news about Intellia Therapeutics Inc (NASDAQ:NTLA) was released by: Prnewswire.com and their article: “Regeneron and Intellia Therapeutics Announce Collaboration to Discover and …” with publication date: April 11, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.